Cargando…

Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study

Aim and Objectives: Direct-acting antiviral (DAA) therapy can cure chronic hepatitis C (CHC), and daclatasvir (DCV)/asunaprevir (ASV) was the first interferon-free DAA therapy introduced in Korea. Patients who achieve sustained virologic response (SVR) after DAA treatment are expected to have good p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Jae-Hyun, Kim, Sung-Eun, Cho, Su-Hyeon, Kim, Gi-Ae, Park, Yewan, Park, Ji-Won, Kang, Seong-Hee, Lee, Young-Sun, Kim, Jeong-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456703/
https://www.ncbi.nlm.nih.gov/pubmed/37629725
http://dx.doi.org/10.3390/medicina59081436
_version_ 1785096763168784384
author Yoon, Jae-Hyun
Kim, Sung-Eun
Cho, Su-Hyeon
Kim, Gi-Ae
Park, Yewan
Park, Ji-Won
Kang, Seong-Hee
Lee, Young-Sun
Kim, Jeong-Han
author_facet Yoon, Jae-Hyun
Kim, Sung-Eun
Cho, Su-Hyeon
Kim, Gi-Ae
Park, Yewan
Park, Ji-Won
Kang, Seong-Hee
Lee, Young-Sun
Kim, Jeong-Han
author_sort Yoon, Jae-Hyun
collection PubMed
description Aim and Objectives: Direct-acting antiviral (DAA) therapy can cure chronic hepatitis C (CHC), and daclatasvir (DCV)/asunaprevir (ASV) was the first interferon-free DAA therapy introduced in Korea. Patients who achieve sustained virologic response (SVR) after DAA treatment are expected to have good prognoses. Therefore, in this study, we aimed to investigate the prognosis of these patients. Materials and Methods: This multicenter prospective observational study included patients with CHC who achieved SVR after DCV/ASV treatment. The primary endpoint was hepatocellular carcinoma (HCC) occurrence, which was reviewed annually. Results: We included 302 patients (median follow-up duration: 38 [16.5–60.0] months; median age: 58 [49–67] years) in the study. Cirrhosis was observed in 103 patients (34.1%), and the median Child–Pugh score was 5.0. HCC occurred in 16 patients (5.3%) within six years post-SVR; these patients were older and had higher cirrhosis prevalence, alpha-fetoprotein levels, and fibrosis-4 index scores than did those without HCC development. Cox proportional hazards analysis revealed that age > 71 years (p = 0.005) and cirrhosis (p = 0.035) were significant risk factors for HCC occurrence. Conclusions: Although the prognoses of patients who achieved SVR with DCV/ASV therapy were generally good, the risk for HCC was present, especially in older patients and in those with cirrhosis. Hence, early treatment at younger ages and regular follow-up surveillance after achieving SVR are warranted.
format Online
Article
Text
id pubmed-10456703
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104567032023-08-26 Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study Yoon, Jae-Hyun Kim, Sung-Eun Cho, Su-Hyeon Kim, Gi-Ae Park, Yewan Park, Ji-Won Kang, Seong-Hee Lee, Young-Sun Kim, Jeong-Han Medicina (Kaunas) Article Aim and Objectives: Direct-acting antiviral (DAA) therapy can cure chronic hepatitis C (CHC), and daclatasvir (DCV)/asunaprevir (ASV) was the first interferon-free DAA therapy introduced in Korea. Patients who achieve sustained virologic response (SVR) after DAA treatment are expected to have good prognoses. Therefore, in this study, we aimed to investigate the prognosis of these patients. Materials and Methods: This multicenter prospective observational study included patients with CHC who achieved SVR after DCV/ASV treatment. The primary endpoint was hepatocellular carcinoma (HCC) occurrence, which was reviewed annually. Results: We included 302 patients (median follow-up duration: 38 [16.5–60.0] months; median age: 58 [49–67] years) in the study. Cirrhosis was observed in 103 patients (34.1%), and the median Child–Pugh score was 5.0. HCC occurred in 16 patients (5.3%) within six years post-SVR; these patients were older and had higher cirrhosis prevalence, alpha-fetoprotein levels, and fibrosis-4 index scores than did those without HCC development. Cox proportional hazards analysis revealed that age > 71 years (p = 0.005) and cirrhosis (p = 0.035) were significant risk factors for HCC occurrence. Conclusions: Although the prognoses of patients who achieved SVR with DCV/ASV therapy were generally good, the risk for HCC was present, especially in older patients and in those with cirrhosis. Hence, early treatment at younger ages and regular follow-up surveillance after achieving SVR are warranted. MDPI 2023-08-08 /pmc/articles/PMC10456703/ /pubmed/37629725 http://dx.doi.org/10.3390/medicina59081436 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yoon, Jae-Hyun
Kim, Sung-Eun
Cho, Su-Hyeon
Kim, Gi-Ae
Park, Yewan
Park, Ji-Won
Kang, Seong-Hee
Lee, Young-Sun
Kim, Jeong-Han
Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study
title Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study
title_full Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study
title_fullStr Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study
title_full_unstemmed Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study
title_short Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study
title_sort prognosis of patients with chronic hepatitis c genotype 1b infection treated using daclatasvir/asunaprevir after sustained virologic response: a 6-year multicenter prospective observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456703/
https://www.ncbi.nlm.nih.gov/pubmed/37629725
http://dx.doi.org/10.3390/medicina59081436
work_keys_str_mv AT yoonjaehyun prognosisofpatientswithchronichepatitiscgenotype1binfectiontreatedusingdaclatasvirasunapreviraftersustainedvirologicresponsea6yearmulticenterprospectiveobservationalstudy
AT kimsungeun prognosisofpatientswithchronichepatitiscgenotype1binfectiontreatedusingdaclatasvirasunapreviraftersustainedvirologicresponsea6yearmulticenterprospectiveobservationalstudy
AT chosuhyeon prognosisofpatientswithchronichepatitiscgenotype1binfectiontreatedusingdaclatasvirasunapreviraftersustainedvirologicresponsea6yearmulticenterprospectiveobservationalstudy
AT kimgiae prognosisofpatientswithchronichepatitiscgenotype1binfectiontreatedusingdaclatasvirasunapreviraftersustainedvirologicresponsea6yearmulticenterprospectiveobservationalstudy
AT parkyewan prognosisofpatientswithchronichepatitiscgenotype1binfectiontreatedusingdaclatasvirasunapreviraftersustainedvirologicresponsea6yearmulticenterprospectiveobservationalstudy
AT parkjiwon prognosisofpatientswithchronichepatitiscgenotype1binfectiontreatedusingdaclatasvirasunapreviraftersustainedvirologicresponsea6yearmulticenterprospectiveobservationalstudy
AT kangseonghee prognosisofpatientswithchronichepatitiscgenotype1binfectiontreatedusingdaclatasvirasunapreviraftersustainedvirologicresponsea6yearmulticenterprospectiveobservationalstudy
AT leeyoungsun prognosisofpatientswithchronichepatitiscgenotype1binfectiontreatedusingdaclatasvirasunapreviraftersustainedvirologicresponsea6yearmulticenterprospectiveobservationalstudy
AT kimjeonghan prognosisofpatientswithchronichepatitiscgenotype1binfectiontreatedusingdaclatasvirasunapreviraftersustainedvirologicresponsea6yearmulticenterprospectiveobservationalstudy